All News

A roundup of some of the most read news and updates in follicular lymphoma in 2020 from CURE®.

The Food and Drug Administration lifted a clinical hold on the MELANI-01 trial, evaluating UCARTCS1A, a CAR T-cell product in patients with relapsed or refractory multiple myeloma.

The study found that the risk increased despite receiving care at a highly specialized center, although neighborhood poverty did not have the same degree of impact on children with the nonmalignant disease.

Here are the top 10 stories from CURE® in 2020.

In an interview with CURE®, Dr. Irene M. Ghobrial discussed smoldering myeloma, a precursor condition that may progress to multiple myeloma, how to proceed if diagnosed with the condition and the available opportunities to participate in clinical trials to learn more.

A roundup of some of the most read news and updates in mantle cell lymphoma in 2020 from CURE®.

Both younger and older women being treated for early breast cancer with chemotherapy are experiencing the same levels of symptom severity and find it a great concern as it interferes with their daily activities.

Here are the top 10 FDA oncology drug approvals that you may have missed this year.

Women with ovarian cancer report a better quality of life when treated with a combination of Keytruda, Avastin and oral metronomic cyclophosphamide.

National guidelines recommend initial surveillance colonoscopy one year after colorectal cancer surgery, but only 57.5% of patients received one in this study due to racial disparities.

Every now and then CURE® is able to get a celebrity to talk about their experience with cancer and share how this common disease even impacts them.

Here are the top 10 episodes of the “CURE Talks Cancer” podcast from 2020.

A roundup of some of the most read news and updates in acute myeloid leukemia in 2020 from CURE®.

From the Ohio state legislature tackling the “fail first” provision insurances put in place to keep patients with advanced cancer on generic drugs that are less effective to COVID-19 becoming the third leading cause of death in the United States behind cancer, here’s what happened in the cancer landscape this week.

Cancer impacts the entire family, and spouses acting as caregivers are experiencing depression and anxiety, without seeking help.

Patients and their doctors should discuss survivorship issues – such as anxiety and fertility issues – sooner rather than later.

Mortality rate for patients with cancer decreases due to Medicaid expansion for patients with newly diagnosed breast, colorectal and lung cancer.

Dr. Mindy Goldman from the UCSF Hellen Diller Comprehensive Care Center, discusses sexual side effects that cancer survivors face, and offers medication and lifestyle fixes to promote healthy and safe sexual encounters.

Keytruda (pembrolizumab), Avastin (bevacizumab) and cyclophosphamide contributed to a clinical benefit in 95% of women in the trial and a durable treatment response of 12 months or longer in 25% of women.

Dr. Sally J. York goes over the types of immunotherapy-related side effects, and what patients with lung cancer and their caregivers should look out for.

The FDA granted a priority review to the supplemental biologics license application for the combination of Keytruda and chemotherapy for the firstline treatment of locally advanced unresectable or metastatic esophageal and gastroesophageal junction cancer.

Researchers try new drug combination to improve overall survival in patients with recurrent high-grade glioma, but are unsuccessful.

The approval of an investigational new drug application will allow Berubicin’s manufacturer to begin studying the investigational drug in adults with glioblastoma who have previously failed their first treatment.

With the second COVID-19 vaccine receiving emergency use authorization by the FDA, patients with cancer undergoing treatment should keep in mind how it may affect their therapy and the potential difference between the two vaccines by Pfizer-BioNTech and Moderna.

This treatment strategy contributed to a median progression-free survival of 13.93 months compared with 9.46 months in those treated with Velcade and dexamethasone.

The decision was based on data that demonstrated sotorasib induced anticancer activity and achieved a positive benefit-risk profile in patients with locally advanced or metastatic non-small cell lung cancer whose disease harbors a KRAS G12C mutation.

An oncology nurse discusses how her peers always provide the best job possible when treating patients with cancer.

A caregiver recognizes the oncology nurse that helped her husband through 9 years of treatment for cancer.